June 20, 2013 by DAVE MIHALOVIC

Prevent Disease

The move by the American Medical Association board means that one-third of the U.S. adult population can now officially be diagnosed and treated with a flood of new drugs and vaccines which have been years in the making.

Everything is calculated and carefully controlled when it comes to the pharmaceutically industry and their sales pimps. That includes national attention to a medical policy makeover that now effectively defines 78 million American adults and 12 million children as having a medical condition requiring treatment.

In the end, members of the AMA’s House of Delegates rejected cautionary advice from their own experts and extended the new status to a condition that affects more than one-third of adults and 17% of children in the United States.

“Recognizing obesity as a disease will help change the way the medical community tackles this complex issue that affects approximately 1 in 3 Americans,” said Dr. Patrice Harris, an AMA board member.

The translation for this statement unencrypted means that the medical community can now legally and effectively prescribe untold numbers of pharmaceuticals including vaccines to a large percentage of the U.S. population. There’s nothing like increasing your client base with one vote.

The vote is also guaranteed to step up pressure on health insurance companies to reimburse physicians for the task of discussing obesity’s health risks with patients.

The AMA’s decision essentially makes diagnosis and treatment of obesity a physician’s obligation. As such, it will encourage primary care physicians to sell more drugs instead of encouraging patients to pursue lifestyle and dietary modifications.

Obesity Vaccines in The Making – The Next Ticking Time Bomb

Last year, a new crop of bogus vaccines were claiming to promote weight loss. A study, published in BioMed Central’s open access journal, Journal of Animal Science and Biotechnology, promoted the claimed benefits of two vaccines which chemically and artificially inhibit the action of natural hormones.

Somatostatin, a peptide hormone, inhibits the action of growth hormone (GH) and insulin-like growth factor (IGF-1), both of which increase metabolism and result in weight loss. The claim by vaccine scientists in the study was to create a vaccine with modified somatostatin causing the body to generate antibodies to somatostatin, effectively removing this inhibition. However, this could also alter and directly interfere with the other hormones and subsequently cause other problems.

“This study demonstrates the possibility of treating obesity with vaccination”, researchers explained. They continued, “Although further studies are necessary to discover the long term implications of these vaccines, treatment of human obesity with vaccination would provide physicians with a drug- and surgical- free option against the weight epidemic.”

Somatostatin is secreted in several locations in the digestive system including the stomach, intestine, and cells of the pancreas. It is also produced by neurons in the brain. The hormone is eventually then carried to the brain’s pituitary gland which is essentially the target where it inhibits the secretion of growth hormones.

The problem is, when you mess with somatostatin pharmacologically through potent inhibitors, you create a host of other physiological disasters, but the study won’t tell you about those. The most frequent adverse effects are hypothyroidism, cardiac conduction changes, gastro-intestinal reactions, gallstones, reduction of insulin release, hyperglycemia or hypoglycemia and even erectile dysfunction.

Artificially inhibiting growth hormones by generating antibodies to somatostatin would also inhibit the secretion of many other hormones, such as gastrin, cholecystokinin, glucagon, insulin, secretin, pancreatic polypeptide, TSH, and vasoactive intestinal peptide, all which are involved in crucial physiological processes for energy expenditure and weight loss.

Weight Loss Drugs For The Obese Conveniently Hit The Market Last Week

Just last week on June 7th, Belviq sold by Eisai, started arriving in pharmacies. It works on brain chemistry to create a feeling of fullness claimed to help obese patients lose an average of about 5% or so of their starting weight.

The wholesale cost of a month’s supply of Belviq to pharmacies is just under $200, says Gary Palmer, chief medical officer for Eisai. The price that patients will pay depends on their insurance coverage and may vary between pharmacies, he says.

Another new diet drug, Qsymia from Vivus helps heavy folks drop about 10% of their weight by suppressing appetite and increasing the feeling of fullness.

Both drugs are targeted to obese patients, but initial sales of Qsymia which was released late last year have been lower than the company expected. So the AMA’s decision will usher in new demands for the drugs as more Physicians begin prescribing them. These medications are new “tools in the toolbox” for doctors who are treating obese patients, says Harvey Grill, president of the Obesity Society. There are several other new obesity drugs on the horizon, and many others being investigated now, he says.

Other diet medications available to treat obesity include phentermine, which suppresses appetite; and orlistat (Xenical), which keeps some dietary fat from being absorbed by the intestine. Orlistat is sold in a lower-dose, over-the-counter version as Alli. All of them have severe side effects including interfering with the absorption of crucial vitamins and minerals, liver and kidner disease, and even cancer.

The Food and Drug Administration, which has approved the two new prescription weight-loss medications, will now face increased pressure to approve new obesity drugs, spurring new drug development and more widespread prescribing by physicians. That is a guarantee.

Our beloved AMA does not want to talk about the chemical terrorism in our food supply, lifestyle habits or any of the REAL problems that cause obesity in our society. Their only concern is how to treat the symptoms of our dysfunctional society. The AMA’s decision is a contrived, manipulated and biased one, controlled by the pharmaceutical industry to protect only one thing…profits!